Participated · Series A · Jun 2026

Icarus Medical develops a new class of orthopedic bracing technologies that combine biomechanics, software, and additive manufacturing to address osteoarthritis, post-operative recovery, neurological conditions, and complex lower-extremity mobility challenges. Key products include the Ascender Knee Brace for patellofemoral and multicompartment osteoarthritis and the Adonis Joint Distraction Knee Brace for unicompartmental osteoarthritis. The company designs and manufactures its products in Charlottesville, Virginia, and plans to expand manufacturing capacity as part of its growth strategy. Icarus intends to advance clinical validation of its devices while accelerating commercialization across the U.S. and hiring additional personnel. Its recent recognition includes placement on the Inc. 5000 list for 1,283% three-year growth and the 2026 CBIC Startup of the Year Award.

Participated · Series E · Mar 2026

Monteris Medical develops the NeuroBlate System, a robotically controlled, MR-guided laser ablation platform that enables minimally invasive treatment of brain tumors and drug-resistant epilepsy in patients aged two and older. The technology, deployed in nearly 130 health systems across North America, delivers precise laser energy to destroy abnormal brain tissue while minimizing collateral damage. Clinical studies cited by the company report short hospital stays, low complication rates, and outcomes comparable to open resection. Monteris plans to use new capital to expand its U.S. commercial footprint, advance technology development, conduct additional clinical research, and pursue geographic expansion. Management reports strong operational results with a near-term pathway to profitability and positive cash flow. The NeuroBlate platform is currently the only LITT system with a robotic interface and published prospective clinical data supporting its safety and efficacy.

Participated · Equity · Apr 2025

hellocare.ai offers a unified, enterprise-ready virtual care platform that combines hardware, software, AI, and an EHR integration engine to deliver AI-Assisted Virtual Nursing, Virtual Sitting, Virtual Consultation, Ambient Documentation, digital whiteboards, patient engagement, Hospital-at-Home, RPM, and Digital Clinic. The company says its end-to-end, in-house technology stack enables rapid customization and integration for health systems. hellocare.ai is already deployed across 70+ health systems and is being rolled out enterprise-wide at AdventHealth across more than 50 hospitals and over 13,000 patient rooms. Bon Secours Mercy Health and UCHealth both participate as investors and customers, illustrating alignment between product roadmap and provider needs. The company plans to use new funding to scale rapidly, deepen its AI capabilities, and expand deployments with leading health systems. Headquartered in Clearwater, Florida, hellocare.ai positions itself as a replacement for fragmented point solutions by delivering measurable ROI and operational impact.

Participated · Series B · Oct 2024

ShiraTronics develops a Migraine Therapy System that delivers neurostimulation intended to reduce headache days and attack severity and improve quality of life for chronic migraine patients. The company reported encouraging reductions in headache days, decreased migraine severity, and improved quality-of-life scores in its first-in-human pilot study. ShiraTronics received Breakthrough Device designation from the FDA's CDRH in 2021. It is now running an FDA-approved pivotal trial (RELIEV-CM2), a multi-center, blinded, randomized, sham-controlled study targeting patients who have failed current medical therapies. The company plans to use new funding to support that pivotal trial, pursue FDA premarket approval, and fund the initial commercial launch of its therapy. Rob Binney serves as CEO and is leading the company through these regulatory and commercialization milestones. ShiraTronics is a Brooklyn Park, Minnesota-based private medical device company focused on an innovative therapy for migraine headaches. The company is developing and clinically testing a neuromodulation technology as its core product. ShiraTronics was spun off from NuXcel, an electrical medical device accelerator. The company is led by President and CEO Lynn Elliott and co-founder and Chairman Mudit K. Jain, PhD. It completed an additional $3M Series A, bringing the Series A to $36M, and intends to use the funds to further accelerate its path to market. ShiraTronics is a Minneapolis-based private medical device company developing an innovative neuromodulation approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology. ShiraTronics was seeded in 2019 as a spin-off from NuXcel, a medical device accelerator managed by co-founder Mudit K. Jain, PhD, and Lynn Elliott. Lynn Elliott joined as President and CEO, with Mudit K. Jain serving as co-founder and Chairman of the Board. Prior to the Series A the company was backed by Strategic HealthCare Investment Partners (S.H.I.P.). In October 2019 ShiraTronics completed a $33M Series A financing to advance its clinical development.

Participated · Equity · Feb 2024

Climate Policy Radar builds an open-source knowledge base that converts complex policy documents into structured information to track global climate change policies. The company applies data science and AI to organize and analyze laws and regulations, providing concise, accurate data to support decision-making. Led by founder Dr. Michal Nachmany, the platform is accessible to a broad audience and is used by nearly 350,000 users across over 100 countries. The recent funding will be used to accelerate the company’s work mapping and analyzing the global climate law and policy landscape. The startup is focused on improving its data infrastructure and analytic capabilities to expand coverage and usability. Financially, it secured over €6.8M in new funding in February 2024 to support those efforts. Founded and led by Dr. Michal Nachmany, Climate Policy Radar has spent roughly 1.5 years developing an open-data and open-source search platform that uses machine learning and natural language processing to collect and analyse massive amounts of policy data at scale. The platform is designed to equip decision-makers with high-quality data to replicate successful policies, avoid failed ones, and increase accountability. The startup has welcomed over 250 civil servants, academics, members of international organisations, and civil society users in its first group and today launched an alpha release. A full commercial launch of services is planned later this year. The team plans to add data on climate litigation cases later this year to track court actions against governments and corporates. Climate Policy Radar has raised £2.1 million to date, primarily via Quadrature Climate Foundation, and is preparing for a new funding round.